

**Remarks**

Upon entry of the above amendments this application will contain claims 1, 2, 5, 6, 8, 16, 19, 21-23, 26, and 33-41. The present application is a national stage filing of PCT/US2004/035513, filed on 8 November 2004, which claims the benefit of United States provisional patent application serial number 60/523,878, filed 20 November 2003. In the current Submission, claims 1, 2, 5, 6, 8, 21, and 26 have been amended. Claims 3, 4, 7, 9-15, 17, 18, 20, and 25 have been canceled, and new claims 33-41 have been added.

In an official communication dated 10 December 2008 restriction to one of the following independent and distinct Groups of inventions was required.

Group I, claims 1-20 drawn to compounds, and

Group II, claims 21-23, 25, and 26 drawn to methods.

Further, election of a single species was required.

The applicants elect to prosecute Group I, claims 1-20 drawn to compounds and select, for initial examination, the species represented by Example 1. New claims 35-37 and claims 1, 2, 5, in part, read on the selected species.

In addition, upon indication of allowable compound claims, the applicants wish to preserve their right to request rejoinder of the Group II invention.

Support for the new claims 35-37 can be found in the application in Examples 1-3, pp 68-71, in the published application, and claim original 7. (All references to the "published application" refer to the published PCT application, WO 05/051898, published 9 June 2008.) Support for new pharmaceutical formulation claim 38 can be found in original claim 16. It is believed that the new claims and claim amendments do not add new matter.

New claims 39-40 have been submitted. These claims are directed to the non-elected invention of Group II. Support for the new method claims 39-41 can be found in original claims 21-23. It is believed that the new claims and claim amendments do not add new matter.

Applicants respectfully request entry of the above amendments and prompt consideration leading to timely allowance of the claimed subject matter. The Examiner is

invited to contact the undersigned attorney by telephone if there are any questions about this Submission or other issues that may be resolved in that fashion.

Respectfully submitted,

/James B. Myers/

James B. Myers  
Attorney for Applicants  
Registration No. 42,021  
Phone: 317-276-0755

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

12 January 2009